Polycyclo Ring System Patents (Class 514/185)
-
Patent number: 9517239Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: July 8, 2015Date of Patent: December 13, 2016Assignee: Infacare Pharmaceutical CorporationInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Patent number: 9480657Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum compound having a heterocycle ligand. Cabazitaxel-platinum nanoparticles are disclosed herein, as well as methods of making and using the same.Type: GrantFiled: March 17, 2014Date of Patent: November 1, 2016Assignee: Tarveda Therapeutics, Inc.Inventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danielle N. Rockwood
-
Patent number: 9365593Abstract: The present invention provides compounds of Formula I: along with compositions comprising the same and methods of using the same, such as for photodynamic therapy in the treatment of cancer.Type: GrantFiled: March 21, 2013Date of Patent: June 14, 2016Assignee: Duke UniversityInventors: Katherine J. Franz, Katie L. Ciesienski
-
Patent number: 9309247Abstract: The present invention provides 2-substituted imidazo[4,5-d]phenanthroline compounds, which are capable of inhibiting proliferation of one or more renal cancer cells, pancreatic cancer cells, prostate cancer cells, colon cancer cells, leukemia cells, brain cancer/tumor cells or non-small cell lung cancer cells.Type: GrantFiled: March 20, 2014Date of Patent: April 12, 2016Assignee: LORUS THERAPEUTICS INC.Inventors: Yoon Lee, Howard Cukier, Venkata Nedunuri, Robert Peralta, Mario Huesca, Aiping H. Young
-
Patent number: 9290528Abstract: The presently-disclosed subject matter includes light-activated ruthenium compounds. In some embodiments the compounds release one or more ligands when exposed to light, and in specific embodiments the light includes a wavelength of about 500 nm to about 1000 nm. The present compounds can also comprise an overall charge, wherein the overall charge can be a positive overall charge or a negative overall charge. Further still, embodiments include methods of treating cancer in a subject by administering a compound and then exposing a site of the subject to light.Type: GrantFiled: March 17, 2014Date of Patent: March 22, 2016Assignee: University of Kentucky Research FoundationInventors: Edith C. Glazer, David K. Heidary
-
Patent number: 9289434Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.Type: GrantFiled: December 18, 2014Date of Patent: March 22, 2016Assignees: Aeolus Sciences, Inc., National Jewish Health, Duke UniversityInventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polivina Jolicia F. Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle
-
Patent number: 9222922Abstract: A high performance liquid chromatography method to routinely and reproducibly detect and quantitate metal complexes is provided. The metal complexes used in the method of the invention can be different metal complexes, or they can be stereoisomers of the same metal complexes. The high performance liquid chromatography method of the present invention is suitable for the separation of diastereomers of the same metal complexes. Also provided is a chiral high performance liquid chromatography method to separate enantiomers of metal complexes. Superoxide dismutase mimetic compounds are also provided.Type: GrantFiled: July 14, 2014Date of Patent: December 29, 2015Assignee: Galera Labs, LLCInventors: Urszula J. Slomczynska, Bobby N. Trawick, Dennis P. Riley, Arati Naik
-
Patent number: 9150837Abstract: Compounds and methods for utilizing compounds comprising a superoxide dismutase mimetic covalently linked to polyethylene glycol. Methods are also provided for preparing a superoxide dismutase mimetic covalently linked to a polyethylene glycol, the methods comprising reacting an activated polyethylene glycol with a superoxide dismutase mimetic, or alternatively, reacting a superoxide dismutase mimetic with an activated polyethylene glycol. A method is also provided for preventing or treating a disease or disorder in which superoxide anions are implicated, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound comprising a superoxide dismutase mimetic covalently linked to a polyethylene glycol. Methods of determining the safety and efficacy of the compounds are also provided. Methods for determining the safety and efficacy can include methods in lab animals and humans.Type: GrantFiled: June 27, 2013Date of Patent: October 6, 2015Assignee: GALERA LABS LLCInventors: Daniela Salvemini, William L. Neumann, Samuel Tremont, Kishore Udipi, Amruta Reddy Poreddy
-
Patent number: 9149483Abstract: The present disclosure relates to methods of treating a range of diseases or conditions. The methods involve administration of a superoxide dismutase mimetic.Type: GrantFiled: September 24, 2012Date of Patent: October 6, 2015Assignee: GALERA LABS, LLCInventors: Jeffery L. Keene, Dennis P. Riley, Robert A. Beardsley
-
Patent number: 9107927Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: August 14, 2014Date of Patent: August 18, 2015Assignee: Infacare Pharmaceutical CorporationInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Patent number: 9090640Abstract: Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C1-6alkylene-phenyl-NH—C(O)—R15, folic acid, ?v?3 integrin RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein R15 is a peptide.Type: GrantFiled: August 30, 2012Date of Patent: July 28, 2015Inventors: Ulrich Bierbach, Song Ding
-
Patent number: 9034862Abstract: The present invention relates to compositions, kits, and methods for treatment of cancers. In some cases, the composition comprises a platinum compound comprising a phenanthridine ligand.Type: GrantFiled: June 21, 2012Date of Patent: May 19, 2015Assignee: Massachusetts Institute of TechnologyInventors: Stephen J. Lippard, Ga Young Park
-
Publication number: 20150125550Abstract: A method of inhibiting cancer cell growth is provided. In some versions, the method includes exposing lung cancer cells or glioma cells to 2,9-di-sec-butyl-1,10-phenanthroline (SBP) or derivatives of SBP in an amount effective to inhibit glioma cell growth. Also, a method of treating a lung cancer or a glioma tumor in a subject in need of such treatment is provided. The method includes administering SBP or derivatives of SBP to the subject in an amount effective to treat the lung cancer or glioma tumor. For either method, the method can further include exposing or administering pseudo five coordinate gold(III) complexes of SBP derivatives.Type: ApplicationFiled: August 29, 2014Publication date: May 7, 2015Inventors: Jack F. Eichler, Clement N. David, Emma H. Wilson
-
Patent number: 9023402Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.Type: GrantFiled: April 1, 2011Date of Patent: May 5, 2015Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
-
Patent number: 9011933Abstract: A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.Type: GrantFiled: January 23, 2005Date of Patent: April 21, 2015Assignee: Biomas Ltd.Inventors: Benjamin Sredni, Michael Albeck
-
Publication number: 20150087612Abstract: Compounds having the general structural formula (I) wherein X can be any element or compound that can form a coordination complex with phthalocyanine and wherein R1; R2, R3 and R4 are independently anionic moieties, or (II) wherein R1; R2, R3 and R4 are independently anionic moieties, are useful in the potentiation of antibiotic activity, and/or in inhibiting or delaying the development of resistance to antibiotics. R1; R2, R3 and R4 may be —S03-. The compounds may be administered to a subject in conjunction with an antibiotic. The antibiotic may be an activator of the SOS response, and may be a DNA gyrase inhibitor or a topoisomerase inhibitor. Compositions and dosage forms comprising the compounds are provided.Type: ApplicationFiled: April 11, 2013Publication date: March 26, 2015Inventors: Clarence Ronald Geyer, Yu Luo
-
Publication number: 20150064120Abstract: The present invention relates to the cosmetic use, as an antidandruff agent, of catalytic oxidation compounds chosen from porphyrins, or of a cosmetic composition comprising the same.Type: ApplicationFiled: February 22, 2013Publication date: March 5, 2015Inventor: Henri Samain
-
Patent number: 8968715Abstract: The invention is generally related to the field of photodynamic therapy by use of photosensitizers and stabilized formulations of the photosensitizers. These formulations may be used to deliver a photosensitizer as a pharmaceutical, agricultural, or industrial agent. The photosensitizer containing formulations and compositions of the invention comprise one or more block copolymers. Furthermore, the invention relates to processes for the production of, and application of, said formulations and compositions as photosensitizer drug delivery systems.Type: GrantFiled: November 17, 2006Date of Patent: March 3, 2015Assignee: The University of British ColumbiaInventors: Rubinah K. Chowdhary, David Dolphin
-
Patent number: 8951969Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.Type: GrantFiled: November 1, 2013Date of Patent: February 10, 2015Assignee: Helsinn Healthcare SAInventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
-
Patent number: 8946202Abstract: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods.Type: GrantFiled: September 5, 2013Date of Patent: February 3, 2015Assignees: Aeolus Sciences, Inc., National Jewish Health, Duke UniversityInventors: James D. Crapo, Brian J. Day, Michael P. Trova, Polvina Jolicia Gauuan, Douglas B. Kitchen, Irwin Fridovich, Ines Batinic-Haberle
-
Patent number: 8946463Abstract: The present invention relates to a chemocatalytic liquid-phase process for the direct one-stage amination of alcohols to primary amines by means of ammonia in high yields using a catalyst system containing at least one transition metal compound and a xantphos ligand.Type: GrantFiled: December 14, 2011Date of Patent: February 3, 2015Assignee: Evonik Degussa GmbHInventors: Florian Klasovsky, Thomas Tacke, Jan Christoph Pfeffer, Thomas Haas, Matthias Beller, Andreas Martin, Jens Deutsch, Angela Koeckritz, Sebastian Imm, Juergen Haberland
-
Patent number: 8940723Abstract: This invention relates to the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof in combination with another antimicrobial agent selected from the group consisting of a beta-lactam antimicrobial agent, mupirocin and chlorhexidine or a pharmaceutically acceptable derivative thereof, for the prevention and/or treatment of microbial infections.Type: GrantFiled: August 5, 2011Date of Patent: January 27, 2015Assignee: Helperby Therapeutics LimitedInventors: Yanmin Hu, Anthony R. M. Coates
-
Publication number: 20150023914Abstract: Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma and/or actinic keratosis is also provided.Type: ApplicationFiled: April 21, 2014Publication date: January 22, 2015Applicant: BioMAS Ltd.Inventors: Benjamin SREDNI, Michael ALBECK
-
Publication number: 20140378427Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum compound having a heterocycle ligand. Cabazitaxel-platinum nanoparticles are disclosed herein, as well as methods of making and using the same.Type: ApplicationFiled: March 17, 2014Publication date: December 25, 2014Applicant: Blend TherapeuticsInventors: Mark T. Bilodeau, Craig A. Dunbar, Timothy E. Barder, Edward R. Lee, Rossitza G. Alargova, Danielle N. Rockwood
-
Publication number: 20140377289Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.Type: ApplicationFiled: September 9, 2014Publication date: December 25, 2014Inventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
-
Publication number: 20140371192Abstract: The present invention relates to alpha-form zinc-phthalocyanine nanowires (ZnPc NWs) having enhanced water solubility and water dispersibility, to a composite of an alpha-form zinc-phthalocyanine nanowire/phenothiazine, to a method for preparing same, and to a photosensitizer including same or a pharmaceutical composition including same for preventing or treating cancers. Since the alpha-form zinc-phthalocyanine nanowires or the composite of alpha-form zinc-phthalocyanine nanowire/phenothiazine according to the present invention exhibit dual traits, i.e., photothermal and photodynamic traits in single molecules, they are very useful for the development of a multifunctional molecular system and can also be usefully applied to light therapy of cancers due to their good light therapeutic effects.Type: ApplicationFiled: August 30, 2012Publication date: December 18, 2014Applicant: POHANG UNIVERSITY OF SCIENCE AND TECHNOLOGY INDUSTRYACADEMY COOPERATION CORPSInventors: Hee Cheul Choi, Hye Kyung Moon, Sang Ho Lee
-
Publication number: 20140364406Abstract: One aspect of the present invention relates to a method of treating or preventing pathologic sequelae of acute hyperglycemia and/or increased fatty acid flux in a subject. This method involves administering an ROS inhibitor to the subject. In addition, methods of promoting neovascularization, inhibiting oxidation or excessive release of free fatty acids, and identifying compounds suitable for treatment or prevention of ROS-mediated injury are also disclosed.Type: ApplicationFiled: July 28, 2014Publication date: December 11, 2014Inventors: Geoffrey C. Gurtner, Michael A. Brownlee
-
Patent number: 8906896Abstract: Acridine containing cisplatin compounds are disclosed that show greater efficacy than other cisplatin compounds for treating cancer. The compounds are compounds of Formula I wherein the variables are defined herein.Type: GrantFiled: October 23, 2009Date of Patent: December 9, 2014Inventor: Ulrich Bierbach
-
Patent number: 8906897Abstract: The invention relates to novel antimicrobial, including antibacterial and antifungal, agents and compositions based on hemin derivatives of general formula (I), and also to the production of novel hemin derivatives. The advantages of antibacterial agents based on hemin derivatives are their biocompatibility, biodegradability, high effectiveness against resistant bacteria and widespread microfungi that are harmful to humans, and freedom from toxicity and side effects.Type: GrantFiled: September 8, 2010Date of Patent: December 9, 2014Assignee: Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises”Inventors: Vladimir Evgenievich Nebolsin, Galina Alexandrovna Zheltukhina
-
Publication number: 20140357610Abstract: A method of reducing caloric intake or food intake in a mammal in need thereof. The method including delivering an effective amount of a compound comprising manganese [III] tetrakis (4-benzoic acid) porphyrin (MnTBAP) or analogs thereof to a mammal over a period of time sufficient to induce a reduction in caloric intake or food intake of the mammal.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventors: Jonathan R. Brestoff Parker, Thomas H. Reynolds, IV
-
Publication number: 20140343028Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.Type: ApplicationFiled: June 11, 2014Publication date: November 20, 2014Inventors: David M. ROTHSTEIN, Chris MURPHY, Vivian WONG, Glenn KAZO
-
Publication number: 20140335025Abstract: Disclosed herein are compositions comprising a targeted corrole nanoparticle; and an acceptable excipient. Also disclosed are compositions comprising a targeted corrole nanoparticle; and an acceptable carrier. Further, disclosed herein are methods of imaging a condition in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; administering an effective amount of the targeted corrole nanoparticle to the subject; and imaging the condition in the subject. In addition, disclosed herein are methods of treating cancer in a subject, comprising providing a composition comprising a targeted corrole nanoparticle; and administering a therapeutically effective dosage of the targeted corrole nanoparticle to the subject.Type: ApplicationFiled: May 8, 2014Publication date: November 13, 2014Applicant: CEDARS-SINAI MEDICAL CENTERInventor: Lali K. MEDINA-KAUWE
-
Patent number: 8877715Abstract: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.Type: GrantFiled: August 18, 2011Date of Patent: November 4, 2014Assignee: Ipsen Pharma S.A.S.Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Patent number: 8877970Abstract: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:Type: GrantFiled: January 8, 2009Date of Patent: November 4, 2014Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: Craig Zimmerman, John W. Babich, John Joyal, Genliang Lu, Kevin P. Maresca, Chris Barone
-
Publication number: 20140308309Abstract: The present invention relates to a composition comprising chlorella extract for preventing or treating liver diseases. The composition comprising the chlorella extract according to the present invention may be applied to medical supplies and health supplementary food and the like, and the chlorella extract of the present invention may be usefully used as a composition for preventing or treating liver diseases because it shows inhibitory effect on liver function injury in a liver function injured model.Type: ApplicationFiled: November 25, 2011Publication date: October 16, 2014Applicant: Gangneung-Wonju National University Industry Academy Cooperation GroupInventors: Hee-Guk Byun, Joong-Kyun Jeon, Se-Kwon Kim, Jung Kwon Lee
-
Patent number: 8859533Abstract: A composition including a Rh or Ru metalloinsertor complex specifically targets mismatch repair (MMR)-deficient cells. Selective cytotoxicity is induced in MMR-deficient cells upon uptake of the inventive metalloinsertor complexes.Type: GrantFiled: May 10, 2012Date of Patent: October 14, 2014Assignee: California Institute of TechnologyInventors: Jacqueline K. Barton, Alexis Komor, Curtis J. Schneider, Alyson Weidmann, Russell Ernst
-
Patent number: 8859760Abstract: Described herein are methods and compositions for killing or preventing the growth of microbes. It has been discovered that a class of porphyrins can kill or prevent the growth of microbes. The porphyrins can be used in a number of different applications where microbes grow.Type: GrantFiled: December 12, 2013Date of Patent: October 14, 2014Assignee: Frontier Scientific, Inc.Inventors: Glenn Prestwich, Jerry C. Bommer, Charles Testa
-
Patent number: 8853128Abstract: Oil-in-water fungicidal formulations are prepared having pigment dispersed therein, the pigment being stable within the oil-in-water emulsion as a result of the addition of suitable silicone surfactants and suitable emulsifiers. The formulations can be prepared either as a 2-pack formulation or as a single formulation. In the case of the single formulation polyethylene glycol is also added. In either case, the formulations show a synergistic effect through the addition of the pigment, the resulting formulations having an increased efficacy. Further, the formulations show a synergistic effect when mixed with conventional chemical fungicides, both being added in reduced amounts compared to recommended rates.Type: GrantFiled: March 15, 2013Date of Patent: October 7, 2014Assignee: Suncor Energy Inc.Inventors: Michael Fefer, Jun Liu, Tomoki Ruo, Sonia Edith Hevia
-
Publication number: 20140287000Abstract: Provided are a tumor proliferation inhibitor and a method for inhibiting tumor proliferation both of which can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound. The present invention provides a tumor proliferation inhibitor containing an ultrasound-sensitive substance and an acoustic cavitation phenomenon-enhancing substance, and provides a method for inhibiting tumor proliferation that can exhibit a tumor proliferation-inhibitory effect using the tumor proliferation inhibitor in combination with low-intensity pulsed ultrasound of a degree that is used in ultrasound diagnosis, and that can be applied to a minimally invasive cancer treatment using low-intensity pulsed ultrasound.Type: ApplicationFiled: February 21, 2014Publication date: September 25, 2014Applicant: FUKUOKA UNIVERSITYInventors: Hirotomo SHIBAGUCHI, Hirofumi TSURU
-
Patent number: 8835416Abstract: Large scale (bulk) compositions comprising high-purity stannsoporfin are disclosed, as well as methods of synthesizing such compositions.Type: GrantFiled: September 5, 2013Date of Patent: September 16, 2014Assignee: Infacare Pharmaceutical CorporationInventors: George S. Drummond, Robert Caroselli, Keith A. Cooke, Daniel Levin, David G. Roe, Christopher P. Boucher
-
Publication number: 20140256795Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.Type: ApplicationFiled: November 1, 2012Publication date: September 11, 2014Inventors: Zhigang He, Duo Jin, Fang Su
-
Publication number: 20140212514Abstract: The invention relates to the use of carbon monoxide (CO) to inhibit the gastrointestinal side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs) and/or alcohol.Type: ApplicationFiled: October 11, 2013Publication date: July 31, 2014Applicant: ALFAMA - Investigacao e Desenvolvimento de Produtos Farmaceuticos, Lda.Inventors: Sandra Sofia Pereira Rodrigues, Joaõ D. Seixas, Bruno Guerreiro, Nuno Miguel Penacho Pereira, Carlos C. Romão, Werner E. Haas, Isabel Goncalves
-
Patent number: 8791099Abstract: Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder.Type: GrantFiled: August 4, 2008Date of Patent: July 29, 2014Assignee: Technion Research and Development Foundation Ltd.Inventors: Zeev Gross, Michael Aviram, Adi Haber, Bianca Fuhrman, Atif Mahammed, Raymond Coleman
-
Publication number: 20140193334Abstract: Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C1-6alkylene-phenyl-NH—C(O)—R15, folic acid, ?v?3 integrin RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein R15 is a peptide.Type: ApplicationFiled: August 30, 2012Publication date: July 10, 2014Inventors: Ulrich Bierbach, Song Ding
-
Patent number: 8771682Abstract: The present invention relates generally to methods and compositions for reducing Interleukin-4 or Interleukin-13 signaling, in particular to treat asthma and atopic dermatitis. The inventors have found that Rac/PAK mediated endocytosis of the ligand bound type I (IL-4R with the chains IL-4Ra and IL-2-Rg) and/or type II receptor (IL-13R with the chains IL-4Ra and IL-13Ra1) is needed for the IL-4 and/or IL-13 mediated activation of downstream signalling events including phosphorylation of Stat family transcrition factors. These discoveries enable new methods of screening compounds that modulate Interleukin-4 and Interleukin-13 signalling, as well as new methods for treating conditions characterized by increased Interleukin-4 and Interleukin-13 levels. These conditions include inflammatory conditions, asthma bronchiale, atopic dermatitis, allergies, atopic syndromes, allergic rhinitis, and th2-induced conditions.Type: GrantFiled: April 26, 2012Date of Patent: July 8, 2014Assignee: Technische Universtität DresdenInventors: Christian Bökel, Thomas Weidemann
-
Patent number: 8765729Abstract: The present invention relates, in general, to cancer therapy, and, in particular, to a method of preventing or treating cancer using low molecular weight antioxidants (e.g., mimetics of superoxide dismutase (SOD)) as the active agent or as a chemo- and/or radio-protectant. The invention also relates to compounds and compositions suitable for use in such a method.Type: GrantFiled: November 9, 2006Date of Patent: July 1, 2014Assignees: Aeolus Sciences, Inc., Duke University, National Jewish Medical and Research CenterInventors: James D. Crapo, Brian J. Day, Ines Batinic-Haberle, Richard Gammans, Zeljko Vusjaskovic
-
Publication number: 20140121191Abstract: The present invention relates to oral dosage formulations consisting of at least one active ingredient contained in a plurality of hydrophobic carriers dispersed in an aqueous medium comprising a hydrocolloid. The active ingredients include various energy supplements, such as caffeine and vitamins. The formulations may further include emulsifiers, permeation enhancers, and vasodilators. The invention further relates to methods of making the oral dosage formulations.Type: ApplicationFiled: March 25, 2013Publication date: May 1, 2014Inventors: Robert Davidson, Eric Allen, Edward Maliski, Jose Bernado
-
Patent number: 8709460Abstract: A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprising a heating step. Also disclosed are the particles made by the above methods and compositions comprising the particles and a base medium.Type: GrantFiled: April 23, 2009Date of Patent: April 29, 2014Assignee: Arch Chemicals, Inc.Inventors: Saeed M. Mohseni, Charles W. Kaufman, David C. Beaty, John J. Jardas, George Polson
-
Patent number: 8709449Abstract: The present invention provides methods and compositions for increasing the effectiveness of photodynamic therapy (“PDT”) and for reducing the duration of skin phototoxicity associated with PDT treatment. The disclosed methods generally include the administration of a lipid composition before, during, or after the administration of photosensitizers used in the PDT treatment protocol. The lipids are preferably phospholipids. It was discovered that the disclosed methods resulted in a more rapid clearance of photosensitizers from the skin and other tissue of patients, which results in a shorter period of skin phototoxicity after PDT treatment. The present invention also provides a composition which is preferably comprised of non-polar photosensitizers and phospholipids.Type: GrantFiled: February 10, 2005Date of Patent: April 29, 2014Assignee: Biolitec Pharma Marketing LtdInventors: Volker Albrecht, Susanna Gräfe
-
Publication number: 20140093517Abstract: Methods for diagnosing and treating conditions associated with life-threatening neurological complications are provided. The methods involve in some aspects the identification of oxLDL and LOX-1 as critical players in pregnant subjects and in some cases subjects having severe preeclampsia (early onset preeclampsia). Related products and kits are also provided.Type: ApplicationFiled: October 3, 2013Publication date: April 3, 2014Inventor: Marilyn J. Cipolla